{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:28:26Z","timestamp":1785914906397,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.prnil.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:02:35Z","timestamp":1759550555000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9659-2411","authenticated-orcid":false,"given":"Kieran","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"G. Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.prnil.2025.09.006_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.prnil.2025.09.006_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1073\/pnas.93.2.749","article-title":"Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase","volume":"93","author":"Carter","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.prnil.2025.09.006_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4111\/icu.20240229","article-title":"Prostate cancer theragnostics biomarkers: an update","volume":"65","author":"Kumar","year":"2024","journal-title":"Investig Clin Urol"},{"issue":"10231","key":"10.1016\/j.prnil.2025.09.006_bib4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prnil.2025.09.006_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.prnil.2025.09.006_bib6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.09.006_bib7","series-title":"A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment","first-page":"1873","author":"Mazzone","year":"2025"},{"issue":"2","key":"10.1016\/j.prnil.2025.09.006_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.09.006_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.prnil.2025.07.001","article-title":"18F-Florastamin PET\/CT in men with clinical suspicion of prostate cancer: a phase I prospective study","author":"Park","year":"2025","journal-title":"Prostate Int"},{"issue":"3","key":"10.1016\/j.prnil.2025.09.006_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.prnil.2025.02.001","article-title":"Pelvic lymph node management in prostate cancer: a narrative review","volume":"13","author":"Chong","year":"2025","journal-title":"Prostate Int"},{"issue":"15","key":"10.1016\/j.prnil.2025.09.006_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153768","article-title":"Clinical applications of PSMA PET examination in patients with prostate cancer","volume":"14","author":"Rasul","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prnil.2025.09.006_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with No metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.prnil.2025.09.006_bib13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","article-title":"PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease","volume":"62","author":"Barbato","year":"2021","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.prnil.2025.09.006_bib14","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.21037\/tau-20-1047","article-title":"Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review","volume":"10","author":"de Kouchkovsky","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.09.006_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.09.006_bib16","series-title":"Population clock & population pyramid","year":"2025"},{"key":"10.1016\/j.prnil.2025.09.006_bib17","series-title":"Prostate cancer projection method changes, updated","year":"2022"},{"key":"10.1016\/j.prnil.2025.09.006_bib18","series-title":"PCOR-ANZ 2023 annual report","year":"2023"},{"key":"10.1016\/j.prnil.2025.09.006_bib19","series-title":"Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial","first-page":"1619","author":"Holzgreve","year":"2023"},{"key":"10.1016\/j.prnil.2025.09.006_bib20","series-title":"Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial","first-page":"1873","author":"de Feria Cardet","year":"2021"},{"issue":"7","key":"10.1016\/j.prnil.2025.09.006_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12149-020-01474-7","article-title":"Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET\/CT in prostate cancer?","volume":"34","author":"Simsek","year":"2020","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.prnil.2025.09.006_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.prnil.2025.09.006_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1754-9485.13162","article-title":"Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: a population-based analysis","volume":"65","author":"Papa","year":"2021","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.prnil.2025.09.006_bib24","year":"2024","journal-title":"Natl Arch Record Adm"},{"key":"10.1016\/j.prnil.2025.09.006_bib25","article-title":"Prostate-specific membrane antigen (PSMA) radiotracers in positron emission tomography \u2013 computed tomography (PET-CT) imaging for individuals with high-risk primary or recurrent prostate cancer","volume":"2025","year":"2025","journal-title":"NHS England"},{"key":"10.1016\/j.prnil.2025.09.006_bib26","series-title":"World class care closer to home","year":"2023"},{"key":"10.1016\/j.prnil.2025.09.006_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.healthplace.2018.08.010","article-title":"Rural dwellers are less likely to survive cancer - an international review and meta-analysis","volume":"53","author":"Carriere","year":"2018","journal-title":"Health Place"},{"key":"10.1016\/j.prnil.2025.09.006_bib28","series-title":"Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer","first-page":"1476","author":"Kelly","year":"2023"},{"key":"10.1016\/j.prnil.2025.09.006_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.prnil.2025.05.003","article-title":"Temporal trends of prostate cancer diagnostics in Australia: has the introduction of a magnetic resonance imaging prostate subsidy fulfilled its cost-saving promises?","author":"Qiu","year":"2025","journal-title":"Prostate Int"},{"issue":"24","key":"10.1016\/j.prnil.2025.09.006_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16244263","article-title":"Current clinical applications of PSMA-PET for prostate cancer diagnosis, staging, and treatment","volume":"16","author":"von Stauffenberg","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.prnil.2025.09.006_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11523-025-01151-7","article-title":"PSMA PET imaging in the management of patients with metastatic castration-resistant prostate cancer treated with radioligand therapy","volume":"20","author":"Kuo","year":"2025","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.09.006_bib32","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1038\/s41598-023-35567-w","article-title":"Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET\/CT in prostate cancer men","volume":"13","author":"Subramanian","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.prnil.2025.09.006_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4111\/icu.20240456","article-title":"Evaluating prostate cancer diagnostic methods: the role and relevance of digital rectal examination in modern era","volume":"66","author":"Chung","year":"2025","journal-title":"Investig Clin Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.09.006_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13550-025-01265-z","article-title":"A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer","volume":"15","author":"Roberts","year":"2025","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.prnil.2025.09.006_bib35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.12688\/f1000research.7161.1","article-title":"Validating the use of medicare Australia billing data to examine trends in skin cancer","volume":"4","author":"Perera","year":"2015","journal-title":"F1000Res"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S228788822500090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S228788822500090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:14:53Z","timestamp":1773843293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S228788822500090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S228788822500090X"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.09.006","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}